Shots in the Dark
The field of cancer immunotherapy is red hot right now. Notably absent from the list are therapeutic cancer vaccines. Only one therapeutic agent that might be considered a vaccine has made it to market, while other once-promising vaccine candidates have failed in recent late-stage efficacy trials. Still, the data emerging from all these studies and others is helping researchers overcome some of the inherent difficulties in designing vaccines that actually work. For a look at recent developments in the field of cancer vaccines check out this article in Genetic Engineering and Biotechnology written by their Technical Editor Patricia Fitzpatrick Dimond, Ph.D.